PFM Health Sciences, LP CMPS COMPASS PATHWAYS PLC

Ownership history in PFM Health Sciences, LP  ·  16 quarters on record

AI Ownership Summary

PFM Health Sciences, LP reported COMPASS PATHWAYS PLC (CMPS) in 16 quarterly 13F filings from 2023 Q4 through 2026 Q1. Peak portfolio weight reached 0.73% in 2025 Q3. The latest visible filing shows CMPS at 0.69% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this CMPS ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was PFM Health Sciences, LP's position in COMPASS PATHWAYS PLC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q1

CMPS was reported at 0.69% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
0.73% in 2025 Q3

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2023 Q4 to 2026 Q1

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

How PFM Health Sciences, LP held CMPS — position size vs. price
% of Fund (quarterly)    CMPS price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 10 quarters  
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q1 ADDED 1,367,099 +587,481 +75.4% 0.69% $7.6M 2026-05-15 $10.37
2025 Q4 REDUCED 53.1% -19.9% 779,618 -883,218 -53.1% 0.54% $5.4M 2026-02-17 $7.63
2025 Q3 REDUCED 6.5% +17.4% 1,662,836 -116,423 -6.5% 0.73% $9.5M 2025-11-14 $5.20
2025 Q2 ADDED 1,779,259 +1,327,992 +294.3% 0.42% $5.0M 2025-08-14 $4.24
2025 Q1 UNCHANGED 451,267 0% 0.09% $1.3M 2025-05-15 $3.95
2024 Q4 UNCHANGED 451,267 0% 0.11% $1.7M 2025-02-14 $4.57
2024 Q3 REDUCED 58.6% -40.5% 451,267 -638,325 -58.6% 0.16% $2.8M 2024-11-14 $4.89
2024 Q2 UNCHANGED 1,089,592 0% 0.33% $6.6M 2024-08-14 $6.87
2024 Q1 ADDED 1,089,592 +750,831 +221.6% 0.43% $9.1M 2024-05-14 $8.17
2023 Q4 ADDED 338,761 +285,890 +540.7% 0.18% $3.0M 2024-02-14 $10.42
6 older quarters hidden  —  Sign in free or upgrade to Premium to see full history

FAQ About PFM Health Sciences, LP and CMPS

These are the practical questions this page is built to answer before you even open the full history table.

How long has PFM Health Sciences, LP reported owning CMPS?

PFM Health Sciences, LP reported CMPS across 10 quarterly 13F filings, from 2023 Q4 through 2026 Q1.

What was the largest reported CMPS position in PFM Health Sciences, LP's portfolio?

The largest reported portfolio weight for CMPS was 0.73% in 2025 Q3.

What is the latest reported CMPS position on this page?

The most recent filing on this page is 2026 Q1, when PFM Health Sciences, LP reported 1,367,099 shares, equal to 0.69% of portfolio, with an estimated market value of $7.6M.

What does the chart on this CMPS ownership page compare?

The chart compares PFM Health Sciences, LP's quarterly CMPS portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did PFM Health Sciences, LP time their CMPS position?

Based on 13F filing dates vs. subsequent CMPS price moves, PFM Health Sciences, LP correctly timed 4 out of 12 reported position changes (33%). The annualised alpha on CMPS relative to SPY over the holding period was -20.4%.

← Back to PFM Health Sciences, LP Holdings